Naseema Gangat
Associate Editor at Blood Cancer Journal
Corespodent at Wiley Online Library
Hematologist @MayoClinic Interests MPN #mpnsm, MDS #mdssm, AML #leusm Alumnus @MayoMN_IMRES @MayoHemeOnc @AKUGlobal Tweets my own
Articles
-
3 weeks ago |
nature.com | Naseema Gangat |Ayalew Tefferi
Venotoclax schedule in acute myeloid leukemia Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy.
-
1 month ago |
onlinelibrary.wiley.com | Natasha Szuber |Paola Guglielmelli |Naseema Gangat
1 Introduction Sex has been identified as a key regulator of susceptibility to cancer, response to therapy, disease outcomes, and associated mortality [1]. The mechanisms underpinning sex-biased disparities include distinct genetic profiles [2], hormone patterns [3], immune responses [4], and drug metabolism [5].
-
1 month ago |
onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi
Conflicts of Interest N.G. has served on the Advisory Board for DISC Medicine and Agios. References 1, , , et al., “Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients,” Mayo Clinic Proceedings 90, no. 12 (2015): 1623–1638, https://doi.org/10.1016/j.mayocp.2015.08.022. 2, , , et al., “One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience,” Mayo Clinic Proceedings 87, no. 1 (2012): 25–33.
-
1 month ago |
onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani
OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss key accomplishments in the myeloproliferative neoplasm (MPN) space, highlighting pivotal developments that have shaped clinical practice, and share their excitement for 2025, including areas primed for significant progress and goals for the coming year. Video content above is prompted by the following:What accomplishments in the MPN space are you most proud of? Which developments stand out as pivotal in shaping clinical practice?
-
1 month ago |
onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani
OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss noteworthy updates in myelofibrosis (MF) from ASH 2024, share their views on the future of MF treatment, offer clinical pearls for community oncologists, and highlight emerging pathways and targets they are excited about for MF management. Video content above is prompted by the following:Dr Kuykendall to faculty: What outstanding updates in MF from ASH 2024 are noteworthy?
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 313
- DMs Open
- No
Wh(V)en less is more in AML Comment on forthcoming article by Willekens et al ://ashpublications.org/blood/article/140/Supplement%201/537/490259/Reduced-Venetoclax-Exposition-to-Seven-Days-of #amlsm @BloodCancerJnl @MayoCancerCare
Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days https://t.co/KHCQoRnwCu
Exapanding the horizon on Ven-HMA in AML-ELN2024 and Mayo Genetic Risk Models #amlsm
Our commentary is out in @AjHematology! "Sharpening the Tools to Get the Edge on Leukemia" with Jacqueline_Garcia on @n_gangat Mayo clinic model (https://t.co/cJxe4YQTBQ) for #AMLsm treated with HMA+VEN. https://t.co/AFbisJwbTL
Most patients with ET can expect a normal life expectancy @MPN_Hub @MPN_RF https://t.co/7i7CDywd8O
Just published @JAMA_current our review on ET Don’t miss the podcast @JAMA_current @MayoHemeOnc @MayoMN_IMRES @NicoGagelmann @VincentRK #mpnsm Review: Essential Thrombocythemia https://t.co/MA7BoA3xOL
